Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment...

Area of Science:

• Oncology
• Nuclear Medicine

Background:

• Metastatic prostate cancer is heterogeneous with variable resistance to current therapies, remaining a leading cause of cancer death.
• Androgen receptor-directed therapy (with or without taxanes) is the standard backbone treatment.
• Radiopharmaceutical therapy presents a novel, non-androgen-directed approach for metastatic castration-resistant prostate cancer.

Purpose of the Study:

• To review the current metastatic prostate cancer treatment landscape, focusing on radiopharmaceutical therapy.
• To discuss 177Lu-PSMA-617, its clinical challenges, and potential combination strategies.
• To introduce emerging radiopharmaceutical therapies for metastatic prostate cancer.

Main Methods:

• Review of current literature on metastatic prostate cancer treatment.
• Focus on radiopharmaceutical therapy, specifically 177Lu-PSMA-617.
• Exploration of clinical challenges and future investigative efforts.

Main Results:

• 177Lu-PSMA-617 demonstrates impact on patient survival in metastatic castration-resistant prostate cancer.
• Clinical challenges exist with 177Lu-PSMA-617, prompting research into combination regimens and earlier use.
• Alternative radiopharmaceutical therapies are under investigation for improved treatment algorithms.

Conclusions:

• Radiopharmaceutical therapy, exemplified by 177Lu-PSMA-617, is a promising personalized treatment modality for metastatic prostate cancer.
• Optimizing the use of radiopharmaceuticals through combination therapies or earlier administration may further enhance patient outcomes.
• Ongoing research into novel radiopharmaceutical agents holds potential for future integration into prostate cancer treatment strategies.